Book description
An expert guide to targeting protein kinases in cancer therapy
Research has shown that protein kinases can instigate the formation
and spread of cancer when they transmit faulty signals inside cells.
Because of this fact, pharmaceutical scientists have targeted kinases
for intensive study, and have been working to develop medicinal
roadblocks to sever their malignant means of communication.
Complete with full-color presentations, Targeting Protein Kinases
for Cancer Therapy defines the structural features of protein
kinases and examines their cellular functions. Combining kinase
biology with chemistry and pharmacology applications, this book
enlists emerging data to drive the discovery of new cancer-fighting
drugs. Valuable information includes:
-
Comprehensive overviews of the major kinase families involved
in oncology, integrating protein structure and function, and
providing important tools to assist pharmaceutical researchers
to understand and work in this dynamic area of cancer drug research
-
Focus on small molecule inhibitors as well as other therapeutic modalities
-
Discussion of kinase inhibitors that have entered clinical
trials for the treatment of cancer, with an emphasis on
molecules that have progressed to late stage clinical trials
and, in a few cases, to market
Providing a platform for further study, this important work reviews
both the successes and challenges of kinase inhibitor therapy, and
provides insight into future directions in the war against cancer.
DAVID J. MATTHEWS is Executive Director of
Oncology Discovery at Exelixis, where he is responsible for cancer
drug discovery. For more than fifteen years, Dr. Matthews has been
involved in drug discovery projects in industry, with particular focus
on small molecule inhibitors. He has twenty scientific publications
and multiple patents to his credit.
MARY E. GERRITSEN is Vice President of Molecular and Cellular
Pharmacology at Exelixis, where she is in charge of cell-based
screening in preclinical research and of biomarker studies for
clinical development compounds in Phase I and II studies. Her prior
industry experience includes positions at Genentech, Bayer and
Millennium Pharmaceuticals. She has authored more than one hundred
peer-reviewed articles and twenty-six book chapters and is an inventor
on forty-two issued patents.
